Profile .pdf


Nom original: Profile.pdfTitre: Layout 1

Ce document au format PDF 1.4 a été généré par QuarkXPress(R) 8.51, et a été envoyé sur fichier-pdf.fr le 01/08/2012 à 19:27, depuis l'adresse IP 86.72.x.x. La présente page de téléchargement du fichier a été vue 1017 fois.
Taille du document: 205 Ko (1 page).
Confidentialité: fichier public


Aperçu du document


16

Interview

Profile

September
August 2010
2012

Interview

August 2012

Bernard Chevalier

17

Fact File
Medical experience
1981–1986
1987

Bernard Chevalier, interventional cardiologist, Cardiovascular Institute Paris-Sud, Jacques Cartier Hospital, Massy, France, talked to
Cardiovascular News about his career, current research and innovations in interventional cardiology. He also spoke about a special
interest in bioresorbable stent trials and his hobbies, including collecting fine wine

1988–1990

1990–1994

Why did you choose medicine as a
career? And why interventional
cardiology?

My choice was strongly influenced by my uncle, who
was a GP in the countryside in Brittany in the sixties. At
that time, his job was really a challenge. During my fellowship in Paris, in the early eighties, I heard about this
new era of interventional cardiology that seemed to be
promising for a few pioneers and decided to move in
this direction.

Which innovations in interventional
cardiology have shaped your career?
I was trained in 1985–1986 when the only tool was the
balloon. At that time we could only play with the size
and duration of inflation. Crossing the lesion was frequently a nightmare in complex cases. Urgent coronary
artery bypass graft (CABG) was the only bailout strategy. Therefore, all new techniques and devices have been
significant landmarks in my practice.

Who were your mentors and what
advice of theirs do you still
remember?
I completed my training in a department headed by one
of the French pioneers, Dr Bernard Lancelin, and continued to work with him for another 10 years. Together,
we gained experience with all the new techniques. The
strongest lesson from him that I still apply is to weigh
up the risks and benefits of a procedure for the patient
before making any decision regarding interventions.
One of his key sayings was “Always think about what
could happen to the patient if this artery were to close
during the intervention”.

Can you describe a memorable case?
Certainly, it was the first bailout stent I implanted. It
was in 1988 and I was treating a young patient, previously grafted, in three vessels. He was unstable, with
occlusion of three native arteries, only one patent graft
in the left anterior descending artery, and the ejection
fraction was very low. A severe dissection and recoil
occurred after several balloon inflations and I failed to
stabilise the situation with prolonged inflations using a
perfusion balloon. We had just received the first few
Palmaz-Schatz stents and decided to use the device as
the risk of urgent CABG was extremely high. It was
clear to us that that tiny device saved his life.



In your opinion, are stents with a
biodegradable polymer the way
forward? Will there be a place for
them if bioresorbable scaffolds prove
successful?

It is now clear that bioabsorbable polymers are a good
answer to the biocompatibility issue raised in the early
era of drug-eluting stents. However, some durable polymers achieve similar results. Also, bioabsorbable polymers do not have the potential to overcome the longterm issues related to the permanent nature of the
current stents, even bare metal ones. Only a bioabsorbable stent can play this role but we need to consolidate its validation with much more data, particularly in
complex lesions. It is intuitively obvious that this technology is interesting for young patients.

You have been involved in the
investigation of new TAVI devices.
How are these devices tackling the
problems still seen with TAVI?

domised controlled trials. A recent example
is the EuroCTO trial, conducted by the
EuroCTO club. CERC is now
working on 27 trials that include
more than 16,000 patients.

their cost-effectiveness. It is too early to understand the
role of multislice computed tomographybased FFR in our practice but if the
preliminary data are confirmed, the
potential of this approach is huge.

In terms of
imaging for
coronary
intervention,
which new
technologies will
you be watching
closely in the
future?

What are your current
topics of research?
New drug-eluting stent technologies, bioabsorbable stents and
TAVI are my main interests. The
next step is mitral valve implantation!

For you, in terms of
content, what was

It is clear that optical coherence tomography (OCT)
has

Most of the new devices are focused on two issues: the
size of vascular access and the positioning/recapturing
properties. Dedicated accessories are also important,
like specific sheaths to limit contraindications to transfemoral approach. We learned a lot from multislice computed tomography for sizing strategies. The most important and recent innovation is not a device but the
development of direct aortic approach, which has the
potential to eliminate the use of the transapical route.
Moderate aortic regurgitation remains a challenge for
TAVI and few new valves are aiming to address this
issue.

the main highlight of EuroPCR 2012?

I think the most important feature of PCR is the quality
of the educational tool. You can easily customise your
programme to your specific needs whatever your level
of expertise. The 2012 edition raised the bar in terms of
interactivity, which is a tough challenge for a meeting of
more than 11,000 attendees!

Of the clinical trials you have
participated in, which did you enjoy
most, and why?
Certainly, the ones I enjoyed most are the different trials
evaluating the BVS absorbable scaffold. This technology has the potential to be the fourth revolution in percutaneous coronary intervention if the financial aspect
does not preclude a large application in young patients.
The LEADERS-FREE trial, sponsored by Biosensors
and organised by CERC, is also a groundbreaking study:
it is a double-blind, randomised, controlled trial comparing a drug-eluting stent to bare metal stents with one
month of dual antiplatelet therapy in patients with contraindications to long dual antiplatelet therapy.

What advice would you give to young
physicians training in interventional
cardiology?
Put the patient (and not only his/her coronary arteries or
his/her aortic stenosis) at the centre of your focus.
Mindset is the key: open mind and self-criticism are crucial. In this fast moving field, we are always learning,
even after 25 years of practice. That makes our job
exciting and gives us the mental strength to, sometimes,
make the decision not to intervene.

You are one of the directors of the
CERC (European Cardiovascular
Research Center). What is the
objective of this organisation and
what has it achieved so far?

What are your interests outside of
medicine?

The major objective of the CERC is to develop clinical research in our field on the basis of a network of
interventional cardiologists working in Europe,
Middle East and Asia Pacific. This medical council, now
with 18 cardiologists, is the major specific feature of our
structure. We aim to develop and conduct trials from
first-in-man to large registries and randomised controlled trials. We have a specific interest in improving
the development of physician-initiated trials to obtain
similar standards achieved with industry-sponsored ran-

As for many other interventional cardiologists, it is difficult for me to get free time for hobbies. Time with my
family, of course, remains the top priority. Whenever
possible, I like to drive my motorbike, even in crowded
Paris. I also enjoy sailing on the Atlantic coast, particularly in Brittany, from where my family originally come
from. I like to travel around the world and have a special
interest in Asia. Another of my hobbies is collecting fine
wines and managing their ageing process. The few thousands of bottles I have give me a very different sense of
time, very different from the permanent rush we experience in cathlabs. The last challenge will be to learn
piano, but that is another story!

the potential to
improve our knowledge of
coronary artery disease. Moreover, its
combination with functional assessments such as FFR is very promising. However, the main limitation of these technologies is



1995–2008

2008–present
2009–present

Cardiology fellow, Paris Hospitals
Assistant of Paris Hospitals,
Cardiology Department at the St
Antoine hospital, Paris
Assistant in the Interventional
Cardiology Department at
Versailles Hospital
Assistant professor,
Interventional Cardiology, MarieLannelongue Hospital
Co-director of the Interventional
Cardiology Department in Centre
Cardiologique du Nord, SaintDenis
Institut Cardiovasculaire ParisSud
Interventional Cardiology Creil

Titles
1987
1994
1997–2001

2002–2004

2003–present
2004–2010
2006–present

2008–present
2012–present

Cardiology board
Executive member of the French
Society of Cardiology
Co-director of Interventional
Cardiology graduate training
Paris University
President of the Interventional
Cardiology Group of the French
Society of Cardiology (GACI)
Fellow of the Society for Cardiac
Angiographies and Interventions
Chief medical editor, PCRonline
Board member of EAPCI
(European association for percutaneous cardiovascular interventions) – Chairman of communication committee (2010–present)
Fellow of European Society of
Cardiology
Fellow of American College of
Cardiology

Clinical trials
n Principal investigator/co-principal investigator of
French trials (Hemostase, Corsica, Open) or
international trials (Class, Lobster, Slide,
Trends, 5F registry, Secure, Brillant I and II,
Milestone I and II, Elutes III, Zomaxx I, Nobori I,
Export, Cristal, Giant, Absorb II)
n Member of steering committee of Rescut, Elute
I and II, Carina, Besmart, Caress, Angioxx registry, Spirit V, Nobori II, Proency
n Director of CERC (Centre Européen de
Recherche Cardiovasculaire)

Congress organisations
1991–1998

Member of organisation committee of “Journée nationale du
groupe de réflexion sur la cardiologie interventionelle”

1997–1999 and
2004–present
Member of scientific committee
of European Congress of
Cardiology
2002–present
Member, scientific committee/programme committee of EuroPCR
2000–present
Member of organisation committee of “High-Tech” congress
2003–present
Co-director of TOPIC (Japan)
2002–2004
Member of the organisation
Committee of Journees
Européennes de la Société
Française de Cardiologie

In this fast moving field, we are always learning, even
after 25 years of practice. That makes our job
exciting and gives us the mental strength to,
sometimes, make the decision not to intervene

BIBA Publishing

BIBA Publishing


Aperçu du document Profile.pdf - page 1/1




Télécharger le fichier (PDF)


Profile.pdf (PDF, 205 Ko)

Télécharger
Formats alternatifs: ZIP



Documents similaires


profile
non cardiac surgery cardiovascular management esc esa 2014
post cardiac arrest syndrome
nejmra1206531
management of pulmonary embolism esc 2014
kodovazenitis et al 2014 journal of periodontal research

Sur le même sujet..